Supplementary Materials

Supplementary Material for:

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management

Xilin Sun, Zunyu Xiao, Gongyan Chen, Zhaoguo Han, Yang Liu, Chongqing Zhang, Yingying Sun, Yan Song, Kai Wang, Fang Fang, Xiance Wang, Yanhong Lin, Lili Xu, Liming Shao, Jin Li, Zhen Cheng,* Sanjiv Sam Gambhir,* Baozhong Shen*

*Corresponding author. Email: shenbz{at}ems.hrbmu.edu.cn (B.S.); sgambhir{at}stanford.edu (S.S.G.); zcheng{at}stanford.edu (Z.C.)

Published 7 March 2018, Sci. Transl. Med. 10, eaan8840 (2018)
DOI: 10.1126/scitranslmed.aan8840

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Synthetic scheme of T-MPG (compound 9) and F-MPG (compound 13).
  • Fig. S2. Radioactivity chromatograms of 18F-MPG.
  • Fig. S3. Characterization of HCC827, H1975, H520, and H358 cell lines and xenograft tumor models in vitro and ex vivo.
  • Fig. S4. Predicted binding modes of F-MPG and PD153035 with the EGFR wild type, EGFR exon 19 E746-A750 deletion homology model, and EGFR L858R/T790M double mutant.
  • Fig. S5. Uptake of MPG analogs in NSCLC cells.
  • Fig. S6. Accumulation of 18F-MPG in different mice tumor xenografts.
  • Fig. S7. Biodistribution of 18F-MPG and 18F-FDG in all patients with NSCLC at 60 min after injection.
  • Fig. S8. Gene sequencing confirmation of an NSCLC patient (number 9) with a shift in tumor from EGFR-activating mutation to EGFR wild type.
  • Table S1. Quantitative 18F-MPG PET ROI analysis of organ uptake in different tumor xenografts in mice at 30 min (n = 6 per group).
  • Table S2. Quantitative 18F-MPG PET ROI analysis of organ uptake in different tumor xenografts in mice at 1 hour (n = 6 per group).
  • Table S3. Quantitative 18F-MPG PET ROI analysis of organ uptake in different tumor xenografts in mice at 2 hours (n = 6 per group).
  • Table S4. Quantitative 18F-FDG PET ROI analysis of organ uptake in different tumor xenografts in mice at 1 hour (n = 6 per group).
  • Table S5. Biodistribution of 18F-MPG in different tumor xenografts in mice at 30 min (n = 6 per group).
  • Table S6. Biodistribution of 18F-MPG in different tumor xenografts in mice at 1 hour (n = 6 per group).
  • Table S7. Biodistribution of 18F-MPG in different tumor xenografts in mice at 2 hours (n = 6 per group).
  • Table S8. First-in-human data, OD in microsievert/megabecquerel.
  • Table S9. 18F-MPG and 18F-FDG SUVmax in all NSCLC patient organs 60 min after injection.
  • Table S10. Tumor accumulation of 18F-MPG and 18F-FDG in different groups of NSCLC patients at 60 min.

[Download PDF]